在治疗严重的斑块性牛皮时使用古塞尔库马布治疗后,横向骨髓炎
Nara Miriam Michaelson1,2, Bart K Chwalisz3,2
1Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA nmichaelson@mgh.harvard.edu.
BMJ case reports
|June 18, 2025
概括
一名接受古塞尔库马布治疗牛皮的患者患有横向髓炎,这是一种罕见的脱髓化疾病. 停止生物治疗后症状有所改善,突出显示这种牛皮治疗可能存在的神经炎症风险.
科学领域:
- 神经免疫学 神经免疫学
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 古塞尔库马布是一种用于治疗严重斑块性牛皮的素-35抑制剂.
- 牛皮的治疗方法,包括生物药物,很少会引发或加剧神经炎症状况.
- 中枢神经系统脱髓化是一种严重的潜在不良事件.
研究的目的:
- 报告用guselkumab治疗的患者中第一个横体髓炎病例.
- 调查古塞尔库马布与脱髓化病变之间的潜在联系.
- 为了提高人们对这种潜在的不良药物反应的认识.
主要方法:
- 一个40多岁的男性患者的病例报告,患有严重的斑块性牛皮.
- 双边下肢麻木的临床表现.
- 宫脊椎MRI显示了急性增强对比度的脱髓化病变.
- 对药物不良反应概率的Naranjo评分评估.
- 审查牛皮治疗方法及其与神经炎症的关联.
主要成果:
- 患者出现了与横向髓炎一致的神经症状.
- 核磁共振扫描 (MRI) 证实了宫脊椎的急性脱髓化病变.
- 在停止使用guselkumab并接受静脉注射甲基prednisolone后,症状显著改善.
- 纳兰乔评分表明可能对guselkumab.b.产生不良药物反应.
结论:
- 这一病例代表了与guselkumab治疗相关的横向髓炎的第一例报告.
- 停用古塞尔库马布和及时治疗导致临床改善.
- 医疗保健提供者应考虑脱髓化风险,特别是在先前存在中枢神经系统病变的患者中.
- 需要进一步的研究才能充分了解古塞尔库马布在神经炎症方面的安全性.
更多相关视频
06:35An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
7.3K
09:20Implanting Glass Spinal Cord Windows in Adult Mice with Experimental Autoimmune Encephalomyelitis
Published on: December 21, 2013
7.6K
相关概念视频
01:20Myasthenia Gravis: Overview and Treatment
2.0K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.0K
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
210
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
210
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
278
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
278